



# Johnson & Johnson (JNJ)

Updated October 15<sup>th</sup>, 2025 by Nathan Parsh

## Key Metrics

<b>Current Price:</b>	\$192	<b>5 Year Annual Expected Total Return:</b>	7.7%	<b>Market Cap:</b>	\$461 B
<b>Fair Value Price:</b>	\$184	<b>5 Year Growth Estimate:</b>	6.0%	<b>Ex-Dividend Date:</b>	11/25/25
<b>% Fair Value:</b>	104%	<b>5 Year Valuation Multiple Estimate:</b>	-0.8%	<b>Dividend Payment Date:</b>	12/09/25
<b>Dividend Yield:</b>	2.7%	<b>5 Year Price Target</b>	\$247	<b>Years Of Dividend Growth:</b>	63
<b>Dividend Risk Score:</b>	A	<b>Sector:</b>	Health Care	<b>Rating:</b>	Hold

## Overview & Current Events

Johnson & Johnson is a diversified health care company and a leader in the area of innovative medicines and medical devices Johnson & Johnson was founded in 1886 and employs nearly 138,000 people around the world. The company is projected to generate more than \$93 billion in revenue this year.

On January 13<sup>th</sup>, 2025, the company announced that it had agreed to acquire Intra-Cellular Therapies (ITCI) for \$14.6 billion. ITCI specializes in therapeutics for central nervous system disorders.

On April 15<sup>th</sup>, 2025, Johnson & Johnson announced that it was increasing its quarterly dividend 4.8% to \$1.30, extending the company's dividend growth streak to 63 consecutive years.

On October 14<sup>th</sup>, 2025, Johnson & Johnson reported third quarter results for the period ending September 30<sup>th</sup>, 2025. For the quarter, revenue grew 6.7% to \$24 billion, which was \$240 million more than expected. Adjusted earnings-per-share of \$2.80 compared favorably to \$2.42 in the prior year and was \$0.04 ahead of estimates.

Revenue for Innovative Medicines grew 6.8% on a reported basis and 5.3% on an operational basis. Infectious Disease decreased 0.9% on a reported basis as growth in *Edurant*, which is used to treat HIV, was more than offset by weakness in the rest of the portfolio. Oncology grew 21.3% due to ongoing high demand for *Darzalex*, which treats multiple myeloma, and continued high demand in several other products. Immunology fell 9.8%. Weakness for *Stelara*, which treats immune-mediated inflammatory diseases, was once again due to biosimilar competition. Offsetting this was ongoing market share gains for *Tremfya*, which treats chronic inflammatory conditions such as plaque psoriasis and arthritis. *Remicade*, which treats autoimmune diseases such as Crohn's disease, benefited from a one-time favorable patient mix adjustment. Revenue for MedTech grew 6.8% on a reported basis and 5.6% on an operational basis. Cardiovascular continues to produce excellent results, as sales were higher by 12.6% due to new products. Surgery had sales growth of 4.4% as gains in biosurgery and endocutters was offset by tougher competition in energy. Orthopaedics returned to growth, with revenue improving 3.8% due to new products and an increase in demand for knees and hips products. The company announced that it plans to separate its orthopedics business into a standalone company called "DePuy Synthes" within the next 18 to 24 months.

Johnson & Johnson offered revised guidance for 2025 as well. The company now expects revenue in a range of \$93 billion to \$93.4 billion, up from \$92.7 billion to \$93.1 billion for the year, \$91.6 billion to \$92.4 billion, and \$90.9 billion to \$91.7 billion previously. Adjusted earnings-per-share are still projected to be in a range of \$10.80 to \$10.90 compared to \$10.50 to \$10.70 and \$10.75 to \$10.95 previously.

## Growth on a Per-Share Basis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
<b>EPS</b>	\$5.48	\$5.93	\$7.30	\$8.18	\$8.68	\$8.03	\$9.80	\$10.15	\$9.92	\$9.98	<b>\$10.85</b>	<b>\$14.52</b>
<b>DPS</b>	\$2.95	\$3.15	\$3.32	\$3.54	\$3.80	\$4.04	\$4.19	\$4.45	\$4.70	\$4.91	<b>\$5.20</b>	<b>\$6.96</b>
<b>Shares<sup>1</sup></b>	2755	2707	2683	2650	2684	2669	2670	2661	2431	2427	<b>2429</b>	<b>2400</b>

<sup>1</sup> In millions of shares.

Disclosure: This analyst has a long position in the security discussed in this research report.



# Johnson & Johnson (JNJ)

Updated October 15<sup>th</sup>, 2025 by Nathan Parsh

Johnson & Johnson has grown earnings over the past 10 years at a rate of 6.9%. The company managed to grow earnings before, during and after the last recession, showing that the company's products are in demand regardless of market conditions. We expect earnings-per-share to grow at a rate of 6% per year through 2030 due to gains in revenue, acquisitions, and share repurchases. This is consistent with Johnson & Johnson's earnings growth composition in the past, however, most growth will come from revenue expansion as the buyback is good for a low-single-digit share reduction annually.

## Valuation Analysis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Now	2030
Avg. P/E	18.2	19.1	23.9	23.7	15.6	18.2	17.5	17.4	15.8	14.5	17.7	17.0
Avg. Yld.	3.0%	2.8%	2.6%	2.7%	2.6%	2.5%	2.5%	3.0%	3.1%	3.4%	2.7%	2.8%

Shares of Johnson & Johnson have gained \$29, or 17.8%, since our July 18<sup>th</sup>, 2025 update. Using guidance for earnings-per-share for the year, Johnson & Johnson trades with a price-to-earnings ratio of 17.7, which is above our target price-to-earnings ratio of 17.0. Multiple compression could reduce annual returns by 0.8% through 2030.

## Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Payout	54%	53%	46%	43%	44%	50%	43%	44%	47%	49%	48%	48%

Even after 60+ years of dividend growth, Johnson & Johnson has a reasonably low dividend payout ratio. This gives the company ample room to raise its dividend, even in a prolonged recession. One of Johnson & Johnson's key competitive advantages is the size and scale of its business. The company is a worldwide leader in a number of healthcare categories. Johnson & Johnson's diversification allows it to continue to grow even if one of the segments is underperforming. The recent separation of the consumer businesses should allow the company to unlock value for shareholders as the faster growing segments, Innovative Medicines and MedTech, could receive a higher multiple from the market.

## Final Thoughts & Recommendation

Following third quarter earnings results, Johnson & Johnson is expected to offer a total annual return of 7.7% through 2030, down from our prior forecast of 11.3%. Our projected return stems from a 6% earnings growth rate and a starting yield of 2.7% that are partially offset by a small amount of multiple contraction. Johnson & Johnson produced another strong quarter and raised its revenue guidance for the year as well. The company has an impressive dividend growth streak and receives a Dividend Risk Score of "A". We maintain our five-year price target of \$247 due to guidance for 2025, but we now rate shares of Johnson & Johnson as a hold due to projected returns.

## Total Return Breakdown by Year



Disclosure: This analyst has a long position in the security discussed in this research report.



# Johnson & Johnson (JNJ)

Updated October 15<sup>th</sup>, 2025 by Nathan Parsh

## Income Statement Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	70,074	71,890	76,450	81,581	82,059	82,584	93,775	94,943	85,159	88,821
Gross Profit	48,538	50,101	51,011	54,490	54,503	54,157	63,920	63,854	58,606	61,350
Gross Margin	69.3%	69.7%	66.7%	66.8%	66.4%	65.6%	68.2%	67.3%	68.8%	69.1%
D&A Exp.	3,746	3,754	5,642	6,929	7,009	7,231	7,390	6,970	7,486	7,339
Operating Profit	18,289	20,891	18,897	21,175	20,970	19,733	23,647	23,703	22,009	22,149
Operating Margin	26.1%	29.1%	24.7%	26.0%	25.6%	23.9%	25.2%	25.0%	25.8%	24.9%
Net Profit	15,409	16,540	1,300	15,297	15,119	14,714	20,878	17,941	35,153	14,066
Net Margin	22.0%	23.0%	1.7%	18.8%	18.4%	17.8%	22.3%	18.9%	41.3%	15.8%
Free Cash Flow	16,106	15,541	17,777	18,531	19,918	20,189	19,758	17,185	17,778	18,059
Income Tax	3,787	3,263	16,373	2,702	2,209	1,783	1,898	3,784	1,736	2,621

## Balance Sheet Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets (\$B)	133.4	141.2	157.3	153.0	157.7	174.9	182.0	187.4	167.6	180.1
Cash & Equivalents	13,732	18,972	17,824	18,107	17,305	13,985	14,487	14,127	21,859	24,105
Acc. Receivable	10,734	11,699	13,490	14,098	14,481	13,576	15,283	16,160	14,873	14,842
Inventories	8,053	8,144	8,765	8,599	9,020	9,344	10,387	12,483	11,181	12,444
Goodwill & Int.	47,393	49,681	85,134	78,064	81,282	89,795	81,638	93,556	70,733	81,818
Total Liabilities (\$B)	62.26	70.79	97.14	93.20	98.26	111.62	107.99	110.57	98.78	108.6
Accounts Payable	6,668	6,918	7,310	7,537	8,544	9,505	11,055	11,703	9,632	10,311
Long-Term Debt	19,861	27,126	34,581	30,480	27,696	35,266	33,751	39,659	29,332	36,634
Total Equity	71,150	70,418	60,160	59,752	59,471	63,278	74,023	76,804	68,774	71,490
LTD/E Ratio	0.28	0.39	0.57	0.51	0.47	0.56	0.46	0.52	0.43	0.51

## Profitability & Per Share Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Assets	11.7%	12.0%	0.9%	9.9%	9.7%	8.8%	11.7%	9.7%	19.8%	8.1%
Return on Equity	21.9%	23.4%	2.0%	25.5%	25.4%	24.0%	30.4%	23.8%	48.3%	20.1%
ROIC	17.2%	17.5%	1.4%	16.5%	17.0%	15.8%	20.2%	16.0%	32.8%	13.6%
Shares Out.	2,755	2,707	2,683	2,650	2,684	2,669	2,667	2,661	2,560	2,429
Revenue/Share	24.91	25.78	27.85	29.90	30.57	30.92	35.07	35.64	33.26	36.56
FCF/Share	5.73	5.57	6.48	6.79	7.42	7.56	7.39	6.45	6.94	7.43

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.